See below... Myelodysplastic syndrome (mds) is not a procedure but a form of bone marrow cancer that is generally less aggressive than leukemia but still malignant. Mds usually evolves more slowly then leukemia and sometimes can transform into acute leukemia and become more aggressive and faster evolving. It can be treated with chemotherapy or bone marrow transplant but sometimes treatment is not necessary.
Myelodysplastic . Myelodysplastic syndrome (mds) is a category of blood disorder, whereby, the bone marrow is unable to produce normal blood cells (red cells, white blood cells and/or platelets). Common presentations include one or more of the following: anemia (low red blood cell count), low white blood cell count and/or thrombocytopenia (low platelet count). This is a common illness is older persons. The severity of mds ranges from mild anemia (refractory anemia) to that of advance illness with a pre-leukemia syndrome. Advanced stage mds may evolve to acute leukemia over time. Treatment options for mds vary based upon the extent of the disease and age. For patients with poor risk mds, bone marrow transplant therapy may be a treatment option. For earlier stage/good risk mds, options may include observation or medications that are designed to allow the bone marrow cells to mature and enter into the blood system. For more information, visit www.Mds-foundation.Org.
Myelodysplastic . Myelodysplastic syndrome (mds) is not a procedure, it is a diagnosis. Sometimes called pre-leukemia, it is really a form of leukemia. It is diagnosed by bone marrow biopsy. Various prognostic factors can predict how people will do. Various treatment options depend on the disease and the patient but include: observation, transfusions, growth factors, and various chemotherapies. Clinical trials should be considered if available.